Development of new immunoassays for biologics generated by transgenic mice method
| Project/Area Number |
18K08002
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
Andoh Akira 滋賀医科大学, 医学部, 教授 (90252395)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 炎症性腸疾患 / IgG / 治療 / 抗体製剤 |
|---|
| Outline of Final Research Achievements |
We developed new assays for serum ustekinumab trough and AUA levels. These assays might provide new insights into therapeutic drug monitoring-based management of Crohn's disease patients under ustekinumab therapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
完全ヒト型生物学的製剤の体内薬物動態を明らかにし、トランスジェニックマウス法による完全ヒト型生物学的製剤血中濃度と中和抗体血中濃度を指標とした完全ヒト型生物学的製剤の効果を最大限に引き出す炎症性腸疾患テーラーメイド免疫療法のストラテジーを構築する基板を確立した。
|
Report
(4 results)
Research Products
(3 results)
